According to NCCN guidelines, docetaxel and cyclophosphamide (TC) and anthracycline and cyclophosphamide (AC/EC) are all optional chemotherapy regimens for lymph node-negative, hormone receptor (HR)-positive, human epidermal growth receptor 2 (HER2)-negative breast cancer patients [7]. This evidence concerns the gene NR4A1 and breast cancer.